01-03-2010 | Editorial
Biomarkers and acute kidney injury: dining with the Fisher King?
Published in: Intensive Care Medicine | Issue 3/2010
Login to get accessExcerpt
Despite its limited utility, the serum creatinine remains an essential part of both the RIFLE and AKIN criteria for the diagnosis of acute kidney injury (AKI) [1]. Due to the delayed rise in creatinine following injury, nephrologists and intensivists alike continue to search for the holy grail of AKI: an early and reliable biomarker of kidney injury. Biomarkers are biological parameters that may indicate normal or pathological processes or responses to interventions and may be objectively quantified. The sensitivity, specificity and time course of a biomarker are critical factors in determining its use in any disease process. But more importantly, the utility of a biomarker depends on the purpose it is expected to fulfill. Summarzing current literature, it appears that an ideal biomarker for AKI should fulfill the following criteria:-
It should distinguish pre-renal AKI from apoptotic and necrotic injury
-
It should be specific for renal injury in the presence of concomitant injury involving other organs
-
It should allow timing of the onset or stage of injury
-
It should predict outcome
-
In the end it should act as surrogate end point useful for clincial interventional studies